RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Desperate!!!Canadian Banks especially, will be looking in depth re: the shorters..... Multiples activities from buying on borrowed money, covering, selling, will stop. Yay!!! Now, RTI price is fantastic. Huge opportunity. I'll take it. Don't doubt 2 secs re: what's coming. You'd be a fool.
This is an exciting development for Aurora, but the stock also offers nice value in the aftermath of legalization. Experts are predicting supply issues in the first months of legalization, and the top producers will be leaned on to close the gap in 2019. Aurora has poured record amounts of cash into its expansion and has been determined to boost its production capacity.
On October 17, Aurora announced that its Aurora Sky facility had been granted its sales license by Health Canada. The company reported that the facility is presently growing approximately 120,000 plants in its licensed flower rooms. At full capacity, Aurora Sky will be capable of producing over 100,000 kilograms of dried cannabis per annum. Aurora currently has funded capacity of over 500,000 kilograms per annum. It has established itself as a legitimate heavyweight among the top producers.
Shares of Aurora were up 43% in 2018 as of close on October 18. The company has managed to roll off all-time highs in October, but it still boasts an attractive price compared to its peers. The addition of MedReleaf propelled Aurora to post the highest revenue total of any other licensed producer in its fiscal 2018 fourth quarter and full-year results.
Aurora has the potential to pass $400 million in revenue in fiscal 2019, and could post over $1 billion in revenue by fiscal 2020, assuming its own rollout goes smoothly. Exposure south of the border should bolster Aurora’s volumes in late October and beyond and should also provide Aurora with ample opportunity to raise more cash and continue its aggressive expansion.